GSK’s $10.6 Billion Acquisition of Nuvalent Highlights Strategic Expansion in Oncology and Legal Expertise
GlaxoSmithKline Plc (GSK) has announced its acquisition of Nuvalent Inc. for a considerable $10.6 billion. This strategic move is expected to bolster GSK’s oncology portfolio, reinforcing its commitment to innovation in cancer treatment. The transaction is set to bring Nuvalent’s promising pipeline of kinase inhibitors into GSK’s fold, potentially accelerating the development of new therapeutic…